InspireMD Inc（NSPR）股票分析

AI 分析 of InspireMD Inc (NSPR)

買進

InspireMD Inc (NSPR) presents a compelling buying opportunity at the current price of $0.6972, especially considering its recent 5-day price surge of 54.93% and a strong RSI of 66.707, indicating bullish momentum. The company has shown significant revenue growth of over 120% year-over-year in Q1 2026, despite facing regulatory challenges, which reflects its potential for recovery and growth. However, the main risk lies in the company's ongoing financial struggles, as evidenced by a forward P/E ratio of 11.6959 and a net income loss of $14,324,000 in Q2 2026, which could impact future profitability. Overall, the positive catalysts from FDA approvals and strong recent performance outweigh the risks, making it a favorable buy at this time.

估值指標

InspireMD Inc（NSPR）目前預期本益比為 11.70，5 年平均預期本益比為 0.18。

預期本益比

嚴重高估

5 年均值 P/E

0.18

目前P/E

11.70

高估

5.47

低估

-5.10

預期 EV/EBITDA

合理

5 年均值 EV/EBITDA

-0.52

目前EV/EBITDA

-0.10

高估

0.11

低估

-1.14

預期股價營收比

低估

5 年均值 P/S

5.05

目前P/S

1.48

高估

8.45

低估

1.65

Alphio AI 對 NSPR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%NSPR

$2.97

情境價格

基

基準

基準 · 50%NSPR

$2.53

情境價格

悲

悲觀

悲觀 · 25%NSPR

$2.25

情境價格

NSPR 常見問題 —— 由 Alphio AI 解答

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InspireMD Inc (NSPR) presents a compelling buying opportunity at the current price of $0.6972, especially considering its recent 5-day price surge of 54.93% and a strong RSI of 66.707, indicating bullish momentum. The company has shown significant revenue growth of over 120% year-over-year in Q1 2026, despite facing regulatory challenges, which reflects its potential for recovery and growth. However, the main risk lies in the company's ongoing financial struggles, as evidenced by a forward P/E ratio of 11.6959 and a net income loss of $14,324,000 in Q2 2026, which could impact future profitability. Overall, the positive catalysts from FDA approvals and strong recent performance outweigh the risks, making it a favorable buy at this time.